Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in
preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age in
Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the
vaccine is safe and induces an immune response.